Drug Profile
Intranasal influenza A virus H5N1 vaccine - ProStrakan
Alternative Names: Intranasal H5N1 vaccine - ArchimedesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Archimedes Pharma
- Developer Kyowa Kirin International
- Class Influenza A vaccines; Vaccines
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in United Kingdom (Intranasal)
- 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
- 08 Jun 2010 Phase-I clinical trials in Influenza-A virus H5N1 subtype in United Kingdom (Intranasal)